Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia
© Samuels et al; licensee BioMed Central Ltd. 2010
Received: 29 December 2009
Accepted: 21 April 2010
Published: 21 April 2010
Pre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms. For haematological malignancies, the non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse is one of the most successful models to study paediatric acute lymphoblastic leukaemia (ALL). However, for this model to be effective for studying engraftment and therapy responses at the whole genome level, careful molecular characterisation is essential.
Here, we sought to validate species-specific gene expression profiling in the high engraftment continuous ALL NOD/SCID xenograft. Using the human Affymetrix whole transcript platform we analysed transcriptional profiles from engrafted tissues without prior cell separation of mouse cells and found it to return highly reproducible profiles in xenografts from individual mice. The model was further tested with experimental mixtures of human and mouse cells, demonstrating that the presence of mouse cells does not significantly skew expression profiles when xenografts contain 90% or more human cells. In addition, we present a novel in silico and experimental masking approach to identify probes and transcript clusters susceptible to cross-species hybridisation.
We demonstrate species-specific transcriptional profiles can be obtained from xenografts when high levels of engraftment are achieved or with the application of transcript cluster masks. Importantly, this masking approach can be applied and adapted to other xenograft models where human tissue infiltration is lower. This model provides a powerful platform for identifying genes and pathways associated with ALL disease progression and response to therapy in vivo.
Understanding the complex molecular pathways leading to disease is critical for the development of effective treatment regimes and novel drug targets. Due to research and resource limitations associated with the use of primary patient material, pre-clinical models are essential to expand our knowledge of cancer biology and for the evaluation of new drugs. For pre-clinical testing, cell lines cultured in vitro have been extensively used but their ability to recapitulate primary disease is limited. Therefore, more relevant disease models are of critical importance.
An ideal model would mimic the proliferation and dissemination of cancer cells that occur in vivo and behave in a similar manner in response to chemotherapeutic drug treatment. The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mouse model is currently one of the most successful models with which to study haematological malignancies such as acute lymphoblastic leukaemia (ALL) , whereby patient bone marrow leukaemia cells are directly transplanted into recipient NOD/SCID mice . The kinetics of engraftment reflects the human disease, leading to bone marrow (BM) infiltration, followed by migration to the spleen, peripheral blood and other haematopoietic organs [2–4].
For ALL, although cure rates are exceeding 75%, the development of drug resistance is poorly understood and remains a major cause of morbidity and mortality in children . Importantly, much of our knowledge of the mechanisms underlying drug resistance has been generated in vitro using immortalised cancer cell lines. The extent to which cell lines retain features of the original disease in vivo is a matter of debate . Thus relevant in vivo, pre-clinical models that recapitulate human disease are critical to delineate resistance mechanisms and improve survival.
Primary leukaemia cells engrafted into NOD/SCID mice appear to retain many of the phenotypic and genotypic features of the original specimen [2, 7–10]. Moreover, their drug resistance profile to conventional chemotherapeutics mirrors that of the patient clinical response [2, 10]. Importantly, comparisons have shown that such xenografts more closely resemble their tumour type of origin than in vitro cell lines and have been accurate in predicting efficacious drug combinations and clinically active therapeutics [11–14].
Continuous xenografts can be established by transplanting cells harvested from the spleen of engrafted animals into secondary and tertiary recipient mice . Utilising continuous ALL NOD/SCID xenografts the effects of chemotherapy drugs can be assessed at the molecular level. Thus, the aim of the current study was to characterise gene expression profiling in the continuous ALL xenograft so that it can be used as a model for the development of therapy resistance in vivo. We have previously demonstrated the clinical relevance of gene-expression profiling through the successful identification of markers predictive of ALL disease outcome, drug-resistance and relapse in a number of primary ALL patient cohorts [15–21]. However, to validate the xenograft model system for transcriptional analysis three critical issues needed to be addressed. Firstly, we needed to determine the most appropriate engrafted xenograft tissue for analysis. BM is more commonly isolated from patients, however, the spleen in xenograft mice contains at least seven-fold more leukaemia cells, which makes isolation of these cells more practical for analysis. Thus, we were interested in establishing whether the same gene expression profiles can be obtained from engrafted spleen and BM. Secondly, we wanted to address the reproducibility of the engraftment in both the BM and spleen of independent mice. Phenotypic evidence suggests engraftment in the continuous mouse model is reproducible , however, this has not been examined at the transcriptional level. Finally, when testing the expression of human xenografts we wanted to measure the effect of the host murine tissue. Studies from other xenograft models have demonstrated cross-species hybridisation of mouse RNA to human specific microarrays. Although not extensively characterised, such studies suggest the potential skewing of human gene expression profiles [22–26]. The previous studies were performed using Affymetrix expression arrays designed to target the 3' end of the gene. This region shows the most divergence between mouse and human. To date, the extent of cross hybridisation using the Affymetrix whole transcript Human Gene 1.0 ST array has not been assessed. The goal of the present study was therefore to validate the use of gene expression profiling in the ALL NOD/SCID xenograft model so that it can be used as a pre-clinical model of relapse.
Comparison of BM/spleen transcriptional profiles of ALL xenografts
Pearson correlation summary statistics showing the engraftment reproducibility between bone marrow and spleen xenografts from four independent mice.
ALL.BM - ALL.BM
ALL.BM - ALL.SP
Reproducibility of engraftment
To establish the reproducibility of engraftment in the continuous ALL model, we compared the gene expression profiles of ALL-16 xenografts from the spleen and BM of four independent mice. Pearson correlation coefficients were calculated to compare the reproducibility of the mean signal intensity between biological replicates (Additional file 1). All transcript clusters were compared for pairwise combinations of microarrays (Table 1) and correlations between tissues showed little variation. These results demonstrate excellent reproducibility in the transcriptional profiles of independent mice transplanted with the ALL-16 xenograft. Importantly, this high level of reproducibility was observed when comparing BM or spleen xenografts among independent mice. This high concordance suggests engraftment of leukaemia cells in BM and spleen is highly reproducible in the continuous ALL xenograft model.
Analysis of cross species hybridisation in the ALL xenograft model
Recovery of human tissue from the engrafted murine host introduces the possibility of contamination from the host mouse cells. The ALL xenograft mouse represents a high engraftment model. At harvest, BM, spleen and peripheral blood all reach high levels of human CD45+ cells, with BM and spleen typically containing > 97% (with a range from 90-99%) . Therefore, BM/spleen xenograft preparations are estimated to contain 1-10% mouse cells. We developed an experimental approach to evaluate the effect of residual mouse cells in the presence of 90-100% human ALL cells using the whole transcript Affymetrix microarray platform.
Pearson correlation summary statistics showing the reproducibility of mixing experiments between ALL.90 (90% human ALL) (n = 3) versus ALL.100 (100% human ALL) (n = 8) and ALL.95 (95% human ALL) (n = 3) versus ALL.100 from independent mice.
ALL.90 - ALL.100
ALL.95 - ALL.100
Masking cross species hybridisation
We then identified transcript clusters theoretically susceptible to cross-species hybridisation due to their associated probes having high identity to mouse transcripts. We identified 75,300 probes, which matched the mouse genome with 100% identity and/or with a single base mismatch. Of the 28,869 human transcript clusters targeted by the Human Gene ST 1.0 array our filtering method revealed 1,085 (~3.75%) transcript clusters as candidates susceptible to cross-species hybridisation (Additional file 2).
The current study sought to address the sensitivity of gene expression profiling for human xenografts growing in mice without prior cell separation. Mouse cells, present in xenografts can be separated using lengthy depletion protocols and fluorescent activated cell sorting (FACS) which can have deleterious affects on transcriptional profiles. Several studies, using a variety of xenograft mouse models, have previously examined cross-species hybridisation without prior cell separation [22–26]. These studies were performed using Affymetrix expression arrays designed to target the 3' end of genes. The 3' expression arrays are thought to be relatively insensitive to cross-species hybridisation as there is greater than 10% DNA divergence between mouse and human within the 3' untranslated region (UTR). In contrast, the Human gene 1.0 ST array queries the whole transcript, giving a more accurate reflection of gene expression. Using the whole transcript platform, our results show that mouse cells do not significantly skew cancer expression profiles when xenografts contain 90% or more human cells. Although mouse RNA was found to cross-hybridise to the whole transcript arrays in the absence of human target, when tested in the presence of human RNA (> 90%), the effect on the transcriptional profiles was minimal. Our microarray analysis and theoretical modelling indicated that the design of the whole transcript Affymetrix chips is effective enough to limit aberrant cross-hybridising mouse RNA. Therefore, without prior cell separation, profiling xenografts on whole transcript arrays is possible for high engraftment haematological models.
We developed experimental and in silico derived gene sets to mask probes and transcript clusters potentially susceptible to cross-species hybridisation. Application of the transcript cluster masks to the gene expression profiles of the human/mouse graded mixtures, improved results by removing outliers and reducing variability. While the derived masking approaches outlined in this study were used for a high engraftment model, this masking approach could be applied and adapted to other xenograft model systems where human tissue infiltration is below 90%.
The kinetics of engraftment in the NOD/SCID ALL xenograft model reflect the human disease with BM infiltration, followed by migration to the spleen, peripheral blood and other haematopoietic organs [2–4]. Importantly, our findings suggest that spleen is a practical alternative to BM for profiling xenograft tissue. Microarray analysis revealed no significant difference in the transcriptional signatures of engrafted BM and spleen. Moreover, we determined that the process of leukaemia engraftment is highly concordant and reproducible between independent mice.
Characterisation of reliable pre-clinical models to identify the most promising new agents to enter clinical trials and molecular events underlying drug resistance is of critical importance. For childhood cancers, xenograft models have been particularly accurate in identifying clinically active agents and effective drug combinations. The continuous NOD/SCID xenograft model for ALL provides a powerful platform with which to study and monitor drug resistance phenotypes in vivo. In this report we have evaluated the accuracy of molecular signatures derived from xenografts. We demonstrate that species-specific transcriptional profiles can be obtained from xenografts when high levels of engraftment are achieved or with the application of transcript cluster masks. Ultimately, using the continuous xenograft model, this experimental approach will allow the molecular analysis of the effects of individual drugs and drug combinations as well as the identification of biological mechanisms associated with drug resistance phenotypes in vivo.
T-ALL Xenograft mouse model
The University of New South Wales Animal Care and Ethics Committee approved all experimental procedures involving NOD/SCID mice. The ALL-16 xenograft line was established from a patient T-ALL diagnosis sample in the Non-Obese Diabetic/Severe Combined Immunodeficient (NOD/SCID) mouse line as previously reported . Briefly, cells harvested from the spleens of engrafted animals were transplanted into secondary, tertiary and quaternary recipient mice to establish a continuous xenograft model. Quaternary xenografts were used in this study. Engraftment and disease progression was monitored by flow cytometric enumeration of the proportion of human versus mouse CD45+ (%huCD45+) cells in peripheral blood using established procedures [2, 10]. When the %huCD45+ reached 50%, animals were culled and tissue was harvested.
Tissue harvested was femoral bone marrow and spleen from xenografted animals, and spleen from non-engrafted mice. Mononuclear cells from spleen samples were purified by syringe homogenisation, followed by filtration and density gradient centrifugation by Ficoll-Paque (n = 4) (LymphoPrep, Nycomed). Bone marrow cells were collected by flushing both femurs with RPMI 1640 medium (Life Technologies) into a collection tube without density gradient centrifugation (n = 4). All cells were cryopreserved for future use in FCS containing 10% DMSO.
Recovery of human tissue from the engrafted mouse introduces the possibility of contamination from mouse cells. To investigate this further, 95% and 90% cell mixtures were prepared using T-ALL from engrafted femoral bone marrow with the non-engrafted mouse spleen from the NOD/SCID mouse strain (n = 3).
Total RNA was extracted using TRIZOL reagent (Invitrogen) followed by purification with the RNeasy Mini kit (Qiagen). Samples were ethanol precipitated and quantitated by Nanodrop ND-1000 Spectrophotometry (Thermo Scientific). RNA integrity was assessed using the Agilent 2100 Bioanalyzer and the RNA Nano 6000 kit (Agilent Technologies).
Labelling and Hybridisation
Samples were labelled according to manufacturers instructions for the GeneChip WT Sense Target Labelling Protocol (Affymetrix). Briefly, 300 ng of total RNA was reverse transcribed into double stranded cDNA using T7-(N)6 random primers. An in vitro transcription step was carried out overnight to generate cRNA. Using the cRNA as a template we generated cDNA, which was then fragmented, labelled and hybridised onto Affymetrix Genechip Human Gene 1.0 ST Arrays. The arrays interrogate 28 869 well-annotated genes with 764 885 probes. The design of the Human Gene 1.0 ST Array was based on the UCSC hg18 and NCBI Build 36 genome sequence assembly. Arrays were washed and stained using the GeneChip Fluidics Station 450 and scanned with the GeneChip Scanner 3000 7G (Affymetrix). All arrays passed quality control criteria as assessed by Expression Console software (Affymetrix).
Raw data CEL files were normalised using the Robust Multi-Array (RMA-16) algorithm in GeneSpring version GX 10.0.2 (Agilent Technologies). A mean adjustment of the normalised signal intensity was carried out to account for minor batch effects seen in the data. Analysis was performed using R version 2.6.2 [29, 30]. Microarray data from this study can accessed from ArrayExpress, accession number E-MEXP-2648 http://www.ebi.ac.uk/arrayexpress
To enable statistically significant data to be interpolated from small sample sizes we used the limma package from Bioconductor . The data was fitted to a linear model and the probability of differential expression was estimated using an empirical Bayes moderated t-test. The p-values were adjusted for multiple testing using a Benjamini-Hochberg correction . Unsupervised hierarchical clustering and Pearson Correlations were generated using the log2 signal intensities following normalisation. MvA plots were generated in R using the average over the replicates in each group. Mean squared distance (MSD) were calculated in R, ranked transcript cluster signal intensity plots and mean signal histograms were also generated in R. Principal Components Analysis (PCA) based on samples and four components was generated in GeneSpring.
Development of a cross-species making approach
To filter cross-species hybridisation we identified all oligonucleotide probes on the Human GeneChip 1.0 ST array susceptible to spurious signal from mouse RNA using a coupled bioinformatics, in silico and experimental masking approach which is detailed below.
Cross-species hybridisation derived in silico
A murine genomic sequence database was compiled from release 54 of the Ensembl Database . All HuGene array annotation files were obtained directly from the Affymetrix website . The probes, probesets and transcript clusters from these files annotated as targeting core human transcripts (i.e. non Affymetrix control probes) were combined, based on their annotated genomic coordinates, to create a mapping table with a three tier hierarchy where probes belong to probesets that in turn belong to transcript clusters (mapping table available on request). The nucleotide sequences for each probe on the HuGene array were obtained from the Affymetrix probe annotation file. The alignment tool BLAT was used to map human probe sequences to the murine genome sequence database. Probes were considered a hit if they matched a database sequence with 100% identity or with a single base mismatch. The BLAT parameters were optimised to detect the 25 mer probes  with tileSize and stepSize set to 12 and 7 respectively. An in house designed Perl script was then used in conjunction with our mapping table to parse the BLAT output files in order to filter out those transcript clusters containing probesets with large numbers of hit probes. Transcript clusters with high numbers of associated hit probes would be deemed candidates for masking. In this filtering process, probes were systematically removed from any probesets with which they were associated. Following this, those probesets with < 50% of their associated probes remaining were systematically removed from any transcript clusters with which they were associated. Once ≥ 50% of probesets in a transcript cluster had been removed the transcript cluster was then selected as a candidate for masking.
Cross-species hybridisation derived experimentally
An experimental approach was employed to examine cross-hybridisation of mouse mRNA to the Human gene array in the absence of human RNA. Three independent non-engrafted mouse spleen (NES) samples were hybridised to the Human Gene 1.0 ST array, CEL files were imported into GeneSpring version GX 10.0.2 and normalised using the Robust Multi-Array (RMA-16) algorithm. The mean signal intensity of the three biological replicates was used to identify cross-hybridising transcript clusters.
We gratefully acknowledge the staff and patients of the Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, for provision of primary ALL samples from which the continuous xenografts were originally established. This work was supported by the Children's Leukaemia and Cancer Research Foundation (CLCRF), Children's Cancer Institute Australia for Medical Research (CCIA), a fellowship (R.B.L.) and grant from The Australian National Health and Medical Research Council. Children's Cancer Institute Australia for Medical Research is affiliated with The University of New South Wales and Sydney Children's Hospital.
- Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F: An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. Current Pharmaceutical Design. 2008, 14 (21): 2023-2039. 10.2174/138161208785294591.PubMedView Article
- Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM, Rice AM: The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 2002, 99 (11): 4100-4108. 10.1182/blood.V99.11.4100.PubMedView Article
- Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman MH, Phillips RA, Dick JE: A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989, 246 (4937): 1597-1600. 10.1126/science.2595371.PubMedView Article
- Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH: Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol. 2001, 29 (3): 322-329. 10.1016/S0301-472X(00)00669-X.PubMedView Article
- Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet. 2008, 371 (9617): 1030-1043. 10.1016/S0140-6736(08)60457-2.PubMedView Article
- Kamb A: What's wrong with our cancer models?. Nat Rev Drug Discov. 2005, 4 (2): 161-165. 10.1038/nrd1635.PubMedView Article
- Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, Ritter J, Jurgens H, Vormoor J: Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr. 1997, 209 (4): 178-185. 10.1055/s-2008-1043947.PubMedView Article
- Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P, Henze G: Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol. 2000, 17 (8): 635-650. 10.1080/08880010050211349.PubMedView Article
- Dialynas DP, Shao L, Billman GF, Yu J: Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood. Stem Cells. 2001, 19 (5): 443-452. 10.1634/stemcells.19-5-443.PubMedView Article
- Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004, 103 (10): 3905-3914. 10.1182/blood-2003-08-2911.PubMedView Article
- Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R: The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007, 49 (7): 928-940. 10.1002/pbc.21078.PubMedView Article
- Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J: Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008, 14 (14): 4572-4583. 10.1158/1078-0432.CCR-07-5090.PubMed CentralPubMedView Article
- Peterson JK, Houghton PJ: Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004, 40 (6): 837-844. 10.1016/j.ejca.2004.01.003.PubMedView Article
- Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C: Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007, 67 (1): 32-40. 10.1158/0008-5472.CAN-06-0610.PubMedView Article
- Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J, de Klerk NH, Kees UR: The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol. 2005, 131 (4): 447-456. 10.1111/j.1365-2141.2005.05785.x.PubMedView Article
- Hoffmann K, Firth MJ, Beesley AH, de Klerk NH, Kees UR: Translating microarray data for diagnostic testing in childhood leukaemia. BMC Cancer. 2006, 6: 229-10.1186/1471-2407-6-229.PubMed CentralPubMedView Article
- Gottardo NG, Hoffmann K, Beesley AH, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Baker DL, Kees UR: Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2007, 137 (4): 319-328. 10.1111/j.1365-2141.2007.06576.x.PubMedView Article
- Hoffmann K, Firth MJ, Beesley AH, Freitas JR, Ford J, Senanayake S, de Klerk NH, Baker DL, Kees UR: Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index. Br J Haematol. 2008, 140 (6): 656-664. 10.1111/j.1365-2141.2008.06981.x.PubMedView Article
- Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU, Kees UR: Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer. 2009, 100 (12): 1926-1936. 10.1038/sj.bjc.6605072.PubMed CentralPubMedView Article
- Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Hoffmann K, Cummings AJ, de Klerk NH, Kees UR: Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia. 2006, 20 (10): 1731-1737. 10.1038/sj.leu.2404365.PubMedView Article
- Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Brigstock DR, de Klerk NH, Kees UR: High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol. 2007, 138 (6): 740-748. 10.1111/j.1365-2141.2007.06739.x.PubMedView Article
- Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, Rouillard JM, Omenn GS, Hanash S: Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol. 2003, 4 (7): R46-10.1186/gb-2003-4-7-r46.PubMed CentralPubMedView Article
- Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP: Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res. 2005, 3 (3): 119-129. 10.1158/1541-7786.MCR-04-0189.PubMedView Article
- Harrell JC, Dye WW, Harvell DM, Sartorius CA, Horwitz KB: Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis. 2008, 25 (1): 81-88. 10.1007/s10585-007-9105-7.PubMedView Article
- Naef F, Huelsken J: Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks. Nucleic Acids Res. 2005, 33 (13): e111-10.1093/nar/gni104.PubMed CentralPubMedView Article
- Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB: Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer. 2006, 13 (2): 617-628. 10.1677/erc.1.01165.PubMedView Article
- Smyth GK: Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments. Statistical Applications in Genetics and Molecular Biology. 2004, 3 (1): 10.2202/1544-6115.1027.
- Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995, 57 (1): 289-300.
- Ihaka R, Gentleman R: R: A Language for Data Analysis and Graphics. Journal of Computational and Graphical Statistics. 1996, 5 (3): 299-314. 10.2307/1390807.
- Team RDC: R: A language and environment for statistical computing. 2008, R Foundation for Statistical Computing. Vienna, Austria
- Ensembl website. [http://www.ensembl.org/index.html]
- Affymetrix website. [http://www.affymetrix.com/index.affx]
- Blat parameters. [http://genome.ucsc.edu/FAQ/FAQblat#blat8]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.